Sickle Cell Disease
Advertisement
In the one-year, fixed-dose extension period of the ESTIMATE study, mitapivat showed continued safety and efficacy in SCD.
Etavopivat was safe and increased hemoglobin, decreased hemolysis, and improved red blood cells in patients with SCD.
Dr. Vadivelan shared her study on pituitary and pancreatic iron deposition in patients with SCD at the 2024 ASPHO Conference.
Stuart Orkin, MD, has been named as one of Time’s 100 Most Influential People of 2024 for his work in hemoglobin research.
The study compared health care resource use and costs of pediatric patients with SCD compared with matched controls.
Dr. Ansong-Ansongton shared what National Minority Health Month and Celebrate Diversity Month mean to him at ASPHO 2024.
Dr. Ansong-Ansongton described data on the impact of abnormal mitochondrial retention and cold in red blood cells in SCD.
The study evaluated transplant outcomes in pediatric patients with SCD who had a history of red blood cell alloimmunization.
A standardized, local TCD supported by central quality review was implemented effectively in resource-constrained settings.
The two-year event-free survival was estimated to be 82.6%, and the two-year overall survival was 94.1%.
A new bill seeks to add a SCD health home model to state Medicaid programs to improve access and quality of treatment.
A myeloablative conditioning regimen containing thiotepa had promising efficacy and safety in patients with severe SCD.
Zahra Pakbaz, MD, on the Challenges of Hematology Patients Swapping From Pediatric to Adult Programs
Dr. Pakbaz describes some of the difficulties faced by patients with SCD as they switch from pediatric to adult programs.
Reduction of hemolysis significantly predicted postinfusion transduction efficacy in patients with SCD treated with lovo-cel.
Exa-cel eliminated RBC transfusions in patients with transfusion-dependent β-thalassemia.
Hydroxyurea therapy reduced blood transfusion by 75% among pediatric patients in sub-Saharan Africa with sickle cell anemia.
The European Commission has approved the Conditional Marketing Authorization for exagamglogene autotemcel.
Drs. Grant, Sutin, and Lin discuss their pilot study investigating cerebral hemodynamics in infants with sickle cell disease.
Dr. Pakbaz and Dr. Strouse discuss their experiences practicing classical hematology and where the speciality is heading.
Dr. Pakbaz, from the University of California Irvine, shared data on the value of a dedicated classical hematology clinic.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.